Prospective, observational, monocentric, non-interventional study.

In practice, patients with preeclampsia are referred to the hospital for medical management only clinical signs & symptoms and standard biological tests are available for patient individualized care. Hence, a new diagnostic tool to distinguish and stratify the different patients referred is in need of proper triage.

REPORTS study aims to determine the diagnostic utility of 2 preeclampsia biomarkers (sFlt-1/PlGF ratio) in clinical decision making in preeclamptic women.

Data are collected by DACIMA Clinical Suite, according to FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH standards (International Conference on Harmonisation)

Inclusion Criteria:

• Suspected or confirmed preeclampsia
• Singleton pregnancy
• Between 26 weeks of gestation and 37 weeks of gestation & 6 days

Exclusion Criteria:

• Multiple pregnancies

Preeclampsia was defined according to the ACOG (The American College of Obstetricians and Gynecologists). The diagnosis of Preeclampsia was based on clinical judgment and routine laboratory findings at inclusion.

Patients were suspected of Preeclampsia if they:

• presented with new onset hypertension and or proteinuria at or after 20 weeks of gestation
• developed an aggravation of their preexisting hypertension and or preexisting proteinuria
• or if they presented with symptoms such as right upper quadrant abdominal pain or headache with visual disturbances or PE-related findings (low platelets, elevated liver transaminases, Vascular Fetal Growth Restriction)